SCHEMBL6205975

SCHEMBL6205975

CC(C)(C)OC(=O)CS(=O)(=O)c1ccc(Br)nc1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.38
CA12 O43570 4/20 0.37
CA1 P00915 4/20 0.37
CA2 P00918 4/20 0.37
CA9 Q16790 4/20 0.37
CA14 Q9ULX7 1/20 0.37
PHGDH O43175 1/20 0.36
MMP2 P08253 2/20 0.35
MMP9 P14780 2/20 0.35
MMP8 P22894 2/20 0.35
MMP13 P45452 2/20 0.35
ALDH1A1 P00352 2/20 0.35
HSD11B1 P28845 2/20 0.35
POLB P06746 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
GAA P10253 1/20 0.35
KDM4E B2RXH2 1/20 0.34
GPR119 Q8TDV5 5/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8321172 0.86 KMT2A (0.38) KMT2ACA12CA1CA2CA9
SCHEMBL5908693 0.81 PLCG1 (0.47) KMT2ACA1CA2CA9PHGDH
SCHEMBL5908893 0.80 CA12 (0.44) KMT2ACA12CA1CA2CA9
SCHEMBL6207231 0.77 MMP2 (0.54) MMP2MMP9MMP13ALDH1A1
SCHEMBL6932753 0.75 KMT2A (0.48) KMT2ACA1CA2CA9PHGDH
SCHEMBL25228160 0.74 GAA (0.39) KMT2ACA12CA1CA2CA9
SCHEMBL6932007 0.74 HTT (0.53) KMT2AMMP8MMP13ALDH1A1HSD11B1
SCHEMBL2173113 0.73 GAA (0.44) KMT2AMMP2MMP9MMP8MMP13
SCHEMBL3450703 0.73 HSD11B1 (0.42) KMT2APHGDHALDH1A1HSD11B1GAA
SCHEMBL34466603 0.73 HSD11B1 (0.42) KMT2APHGDHALDH1A1HSD11B1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1565459-A2 HETEROARYLSULFONYLMETHYL HYDROXAMIC ACIDS AND AMIDES AND THEIR USE AS PROTEASE INHIBITORS Pharmacia Corporation (US) 2005-08-24 EP disclosed
US-20040142979-A1 Heteroarylsulfonylmethyl hydroxamic acids and amides and their use as protease inhibitors PHARMACIA CORPORATION 2004-07-22 US disclosed
WO-2004048368-A2 HETEROARYLSULFONYLMETHYL HYDROXAMIC ACIDS AND AMIDES AND THEIR USE AS PROTEASE INHIBITORS PHARMACIA CORPORATION (US) 2004-06-10 WO disclosed
WO-2004048368-A2 HETEROARYLSULFONYLMETHYL HYDROXAMIC ACIDS AND AMIDES AND THEIR USE AS PROTEASE INHIBITORS PHARMACIA CORPORATION (US) 2004-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040142979-A1 Heteroarylsulfonylmethyl hydroxamic acids and amides and their use as protease inhibitors MMP3, MMP13, MMP10 KMT2A 1113/4885CA12 436/4885CA1 157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.